BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Shea D, Widmer LA, Stelling J, Egli A. Changing face of vaccination in immunocompromised hosts. Curr Infect Dis Rep 2014;16:420. [PMID: 24992978 DOI: 10.1007/s11908-014-0420-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Trebbien R, Pedersen SS, Vorborg K, Franck KT, Fischer TK. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill 2017;22:30445. [PMID: 28128091 DOI: 10.2807/1560-7917.ES.2017.22.3.30445] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 6.6] [Reference Citation Analysis]
2 Kaufmann L, Syedbasha M, Vogt D, Hollenstein Y, Hartmann J, Linnik JE, Egli A. An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers. J Vis Exp 2017. [PMID: 29286466 DOI: 10.3791/55833] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Scanlon N, Saklawi Y, Rouphael N. The Role of Systems Vaccinology in Understanding the Immune Defects to Vaccination in Solid Organ Transplant Recipients. Front Immunol 2020;11:582201. [PMID: 33324400 DOI: 10.3389/fimmu.2020.582201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Trebbien R, Christiansen CB, Fischer TK. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2. J Clin Virol 2018;102:1-6. [PMID: 29448067 DOI: 10.1016/j.jcv.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Rocca S, Santilli V, Cotugno N, Concato C, Manno EC, Nocentini G, Macchiarulo G, Cancrini C, Finocchi A, Guzzo I, Dello Strologo L, Palma P. Waning of vaccine-induced immunity to measles in kidney transplanted children. Medicine (Baltimore) 2016;95:e4738. [PMID: 27631222 DOI: 10.1097/MD.0000000000004738] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
6 Varghese L, Curran D, Bunge E, Vroling H, van Kessel F, Guignard A, Casabona G, Olivieri A. Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK. Public Health 2017;142:46-9. [PMID: 28057197 DOI: 10.1016/j.puhe.2016.10.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
7 Cotugno N, Ruggiero A, Santilli V, Manno EC, Rocca S, Zicari S, Amodio D, Colucci M, Rossi P, Levy O, Martinon-Torres F, Pollard AJ, Palma P. OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines. J Immunol Res 2019;2019:8732191. [PMID: 31183393 DOI: 10.1155/2019/8732191] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
8 Linnik JE, Egli A. Impact of host genetic polymorphisms on vaccine induced antibody response. Hum Vaccin Immunother 2016;12:907-15. [PMID: 26809773 DOI: 10.1080/21645515.2015.1119345] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]